Cooke & Bieler LP Decreases Stake in Integer Holdings Co. (NYSE:ITGR)

Cooke & Bieler LP lowered its position in Integer Holdings Co. (NYSE:ITGR) by 5.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 298,603 shares of the medical equipment provider’s stock after selling 17,290 shares during the quarter. Cooke & Bieler LP owned about 0.89% of Integer worth $39,571,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Mather Group LLC. increased its holdings in Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Huntington National Bank increased its holdings in Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 268 shares during the last quarter. R Squared Ltd purchased a new stake in Integer in the 4th quarter worth about $44,000. Versant Capital Management Inc increased its holdings in Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 183 shares during the last quarter. Finally, Principal Securities Inc. increased its holdings in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on ITGR shares. Benchmark lifted their target price on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 21st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. KeyCorp lifted their target price on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Finally, Citigroup lifted their price target on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Integer presently has an average rating of “Moderate Buy” and an average target price of $147.67.

Integer Stock Performance

NYSE:ITGR opened at $120.55 on Tuesday. The business has a 50 day moving average of $135.21 and a 200 day moving average of $132.99. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 35.88, a PEG ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a 1-year low of $107.11 and a 1-year high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09.

Integer (NYSE:ITGR) last released its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. On average, sell-side analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.